We further verified the clinical relevance of our findings by evaluating the combined effects of PI3K and STAT3 inhibitors on BCa using primary human patient samples, tissues from bladder tumor bulks of two human patients (Supplementary Table S4) were isolated and injected subcutaneously into the flanks of immune-compromised mice (BALB/c-Nude) when the tumors reached 100 mm3, mice were randomly divided into four groups and subjected with DMSO, copanlisib, napabucasin, or combination (copanlisib and napabucasin) treatments. This evidence concerns the gene STAT3 and urinary bladder neoplasm.